PMID- 37844914
OWN - NLM
STAT- MEDLINE
DCOM- 20231221
LR  - 20231222
IS  - 1752-699X (Electronic)
IS  - 1752-6981 (Print)
IS  - 1752-6981 (Linking)
VI  - 17
IP  - 12
DP  - 2023 Dec
TI  - Safety outcomes of salbutamol: A systematic review and meta-analysis.
PG  - 1254-1264
LID - 10.1111/crj.13711 [doi]
AB  - PURPOSE: Salbutamol has been used to alleviate bronchospasm in airway disease for 
      decades, while its potential risks have not been systematically investigated yet. 
      The risk of any potential adverse events (AEs) in patients treated with 
      salbutamol was assessed through systematic review and meta-analysis. METHODS: A 
      systematic search of the literature was conducted, using EMBASE, PubMed and 
      Cochrane library, until 3 April 2023. Once the AE incidence was evaluated, 
      randomized controlled trials (RCTs) were eligible for review. The endpoints 
      included the incidence of total AEs, severe AEs, treatment discontinuation and 
      specific AEs. The pooled AEs incidence was analysed via random-effects model in a 
      single-arm meta-analysis. A subgroup study was carried out to examine whether the 
      pooled incidence of AE differed by indications or formulations. RESULTS: Of the 
      8912 studies that were identified, 58 RCTs met the inclusion criteria and 
      involved 12 961 participants. The analysis showed the pooled incidences of total 
      AEs, severe AEs and treatment discontinuation in patients treated with salbutamol 
      were 34%, 2% and 3%, respectively. Subgroup analysis indicated that premature 
      labour users and intravenous salbutamol users were more likely associated with 
      total AEs. The most frequently observed specific AEs were palpitations or 
      tachycardia. CONCLUSION: This meta-analysis indicated that salbutamol was 
      associated with a very common risk of palpitations or tachycardia. Clinical 
      vigilance and research efforts are needed to optimize the safe use of salbutamol.
CI  - (c) 2023 The Authors. The Clinical Respiratory Journal published by John Wiley & 
      Sons Ltd.
FAU - Ma, Lan-Hong
AU  - Ma LH
AD  - Department of Respiratory, Digestive, and Cardiology, Children's Hospital of 
      Xinjiang Uygur Autonomous Region, Urumqi, China.
FAU - Jia, Li
AU  - Jia L
AD  - Department of Pharmacy, People's Hospital of Xinjiang Uygur Autonomous Region, 
      Urumqi, China.
FAU - Bai, Ling
AU  - Bai L
AUID- ORCID: 0000-0003-3778-610X
AD  - Department of Nephrorheumatology, Children's Hospital of Xinjiang Uygur 
      Autonomous Region, Urumqi, China.
LA  - eng
GR  - 2021D01A136/Natural Science Foundation of Xinjiang Uygur Autonomous Region/
GR  - 20180311/Technology and Innovation Project of Xinjiang Uygur Autonomous Region 
      People's Hospital/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20231016
PL  - England
TA  - Clin Respir J
JT  - The clinical respiratory journal
JID - 101315570
RN  - QF8SVZ843E (Albuterol)
SB  - IM
MH  - Humans
MH  - *Albuterol/adverse effects
MH  - *Tachycardia
PMC - PMC10730473
OTO - NOTNLM
OT  - adverse events
OT  - meta-analysis
OT  - safety
OT  - salbutamol
OT  - systematic review
COIS- No conflict of interest was associated with this work.
EDAT- 2023/10/17 00:42
MHDA- 2023/12/21 06:43
PMCR- 2023/10/16
CRDT- 2023/10/16 20:32
PHST- 2023/05/18 00:00 [revised]
PHST- 2023/01/19 00:00 [received]
PHST- 2023/09/29 00:00 [accepted]
PHST- 2023/12/21 06:43 [medline]
PHST- 2023/10/17 00:42 [pubmed]
PHST- 2023/10/16 20:32 [entrez]
PHST- 2023/10/16 00:00 [pmc-release]
AID - CRJ13711 [pii]
AID - 10.1111/crj.13711 [doi]
PST - ppublish
SO  - Clin Respir J. 2023 Dec;17(12):1254-1264. doi: 10.1111/crj.13711. Epub 2023 Oct 
      16.